PhD student Sandra Jensen Department of Organ- and Plastic Surgery, Vejle Hospital
Projektet i tal
OPEN undersøgelse/kliniske data
Forventet # af deltagere
Inkluderet antal deltagere
Inkluderede deltagere med prøver
Invasive disease-free survival after neoadjuvant therapy in Breast Cancer
Cohort study on early breast cancer patients investigating a possible effect of neoadjuvant therapy (NAT) on invasive disease-free survival compared to only adjuvant therapy. In the study period NAT was recommended in the event of locally advanced breast cancer to reduce the need for extensive surgery. However, some patients with early breast cancer were also offered NAT if the preliminary investigations demonstrated that the patients would receive adjuvant therapy after the operation.
Chemotherapy is an important part of the neoadjuvant or adjuvant treatment in many early breast cancer patients. In 2019 55 % of Danish breast cancer patients received chemotherapy. Studies have demonstrated that neoadjuvant therapy (NAT) can minimize or eliminate the tumour in both the breast and axilla resulting in less extensive surgery. However, it is still debated whether NAT improve survival compared to adjuvant therapy. The aim of the study is to investigate whether NAT increases invasive disease-free survival in breast cancer (and in whom) in the era of polychemo- and HER2 targeted neoadjuvant therapy compared to adjuvant therapy with a minimum 5-year follow up.
Description of the cohort
Vejle Hospital were pioneers in implementing NAT for early breast cancer in Denmark. In the study period NAT was also considered when the tumour was ≤ 5 cm and one of the following:
1. TNBC and HER2 positive
2. The patient´s preoperative prognostic histopathology (malignancy grade, nodal involvement), age indicated that adjuvant therapy would be part of the treatment.
The reference group of patients that received AT will be identified through the Danish Breast Cancer Group (DBCG). Propensity score matching will be applied. - 1:n (variable) to achieve exchangeability.
-LABC, metastatic disease at the time of diagnosis.
-Only endocrine neoadjuvant therapy
Data and biological material
Clinical data will be extracted through RKKP/DBCG. Additional histopathological data will be extracted through DPDB. Information on recurrence will be found through RKKP/DBCG cross-checked with DPDB and the Danish National Patient Registry (DNPR). Information on survival and emigration will be accessed through the National Registries, Danish Civil Registration System (CRS) and Cause of Death Registry (DAR).
Collaborating researchers and departments
Department of Surgery, Vejle Hospital
Hans B. Rahr
Department of Clinical Oncology, Regional Hospital Gødstrup
Department of Plastic and Breast Surgery Aarhus University Hospital,